Journal of gastroenterology and hepatology · 2025
Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Yu Rim, Woo Hyun Young, Kweon Young Oh, Tak Won Young, Jang Se Young, Park Jung Gil, Kang Min Kyu, Song Jeong Eun, Jang Byoung Kuk, Lee Changhyeong, Kim Byung Seok, Hwang Jae Seok, Chung Woo Jin, Heo Jeong, Heo Nae-Yun, Park Seung Ha, Yoon Jun Sik, Jeong Joonho, Kwak Sang Gyu, Kang Yeowool, Baek Yang Hyun, Park Soo Young
Аннотация
OBJECTIVE: Hepatocellular carcinoma (HCC) can still occur in patients with chronic hepatitis C after achieving a sustained virologic response (SVR) with direct-acting antiviral (DAA) therapy. Therefore, we aimed to identify and validate predictors and HCC risk models using longitudinal data.
METHOD: This retrospective cohort study included patients who achieved SVR after DAA therapy. Model performance was assessed using Harrell's C-index and the area under the time-dependent receiver operating characteristic curve (AUROC).
RESULTS: After excluding patients who developed HCC or died within 1 year after achieving SVR, a total of 2778 patients were finally included in this study. 154 (5.5%) patients developed HCC at a median of 3.3 years. LSM value showed significant improvement after antiviral therapy (all p < 0.05). In the multivariable analysis, LSM at baseline and 1 year after SVR were significantly associated with the occurrence of HCC (all p < 0.05). LSM at 1 year after SVR could better predict HCC risk than baseline LSM (C-index: 0.760, 0.788 at baseline, 1 year after SVR, respectively). Low-risk patients (LSM < 10 kPa) using LSM values at 1 year after SVR (76.4%) showed an incidence risk of 0.482 incidence rate/100 patient-years. In patients with advanced chronic liver disease, LSM at 1 year after SVR demonstrated superior predictive performance for HCC development compared to baseline LSM and other prediction models assessed at various time points (C-index: 0.744, 95% CI: 0.660-0.829; 3-year follow-up AUROC: 0.794, 95% CI: 0.754-0.831).
CONCLUSIONS: LSM after achieving SVR effectively predicts HCC risk, especially in patients with advanced chronic liver disease.
METHOD: This retrospective cohort study included patients who achieved SVR after DAA therapy. Model performance was assessed using Harrell's C-index and the area under the time-dependent receiver operating characteristic curve (AUROC).
RESULTS: After excluding patients who developed HCC or died within 1 year after achieving SVR, a total of 2778 patients were finally included in this study. 154 (5.5%) patients developed HCC at a median of 3.3 years. LSM value showed significant improvement after antiviral therapy (all p < 0.05). In the multivariable analysis, LSM at baseline and 1 year after SVR were significantly associated with the occurrence of HCC (all p < 0.05). LSM at 1 year after SVR could better predict HCC risk than baseline LSM (C-index: 0.760, 0.788 at baseline, 1 year after SVR, respectively). Low-risk patients (LSM < 10 kPa) using LSM values at 1 year after SVR (76.4%) showed an incidence risk of 0.482 incidence rate/100 patient-years. In patients with advanced chronic liver disease, LSM at 1 year after SVR demonstrated superior predictive performance for HCC development compared to baseline LSM and other prediction models assessed at various time points (C-index: 0.744, 95% CI: 0.660-0.829; 3-year follow-up AUROC: 0.794, 95% CI: 0.754-0.831).
CONCLUSIONS: LSM after achieving SVR effectively predicts HCC risk, especially in patients with advanced chronic liver disease.